Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
June 30, 2025 6:00 AM EDTSingle Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins
Pharmacodynamic Effects Supportive of Once-Monthly Dosing
Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year
Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B... More
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
June 29, 2025 5:00 PM EDTROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available... More
